Multiple IDH1 and IDH2 inhibitors are reported, though only one IDH1 inhibitor (ivosidenib) and one IDH2 inhibitor (enasidenib) have been approved for clinical use, i.e. for acute myeloid leukaemia (AML) treatment where the cancer cells make an IDH variant12,13. This evidence concerns the gene IDH1 and acute myeloid leukemia.